Biotechnology is a key market segment for Coherent. We provide innovative solutions for academic research, pharma discovery, translational research, clinical testing, and interventional therapeutics. We support these applications with lasers, laser engines, fibers, and fiber optic components.
Argenx SE to raise €637m
Latest NewsDutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
Lasers to personalise therapy
BackgroundBiotechnology is a key market segment for Coherent. We provide innovative solutions for academic research, pharma discovery, translational research, clinical testing, and interventional therapeutics. We support these applications with lasers, laser engines, fibers, and fiber optic components.
Recombinant production
ProductsSino Biological specializes in recombinant production of antibodies and proteins. The company routinely conducts high-throughput projects of up to 1,000 per batch. Sino Biological’s manufacturing facility can also handle large-scale production at gram level.
Bayer invests into synthetic TCRs for cell therapy
Latest NewsTCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer
Bavarian Nordic bags $225m for licence to RSV vaccine
Latest NewsBavarian Nordic is to receive up to US$225 and double-digit royalties for granting exclusive Chinese commercialisation rights for MVA-BN® RSV to Nuance Pharma.
RTSM benefits: configuration versus customisation
BackgroundIn the 1990s, the first clinical IVR systems (Interactive Voice Response Systems) were developed in order to randomise patients over the phone, and later, to dispense drug and resupply sites as well.
Austria magnet for biotechnology
Sponsored PublicationsThe life sciences location of Austria has gained considerable momentum since the founding of the very first Austrian biotech company Intercell at the turn of the millennium. Today the who’s who of the biotech sector relies on Austria, in particular on its capital city of Vienna.
The Next Big Thing: “Biologisation”
OpinionThe development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy
The Next Big Thing: "Biologisation"
OpinionThe development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy
Switzerland paves the way for genome editing
Latest NewsSwitzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding.